Abstract
Aspirin, Clopidogrel and GpIIb/IIIa antagonists are a mainstay in the treatment and prevention of arterial thromboembolism. Normally their action is not monitored. Several factors are believed to contribute to variations in platelet inhibitors in patients under treatment with one of those drugs. Patient compliance, comorbidities, as well as biological variables such as platelet count, receptor density, etc. Many monitoring methods have been proposed for the monitoring of anti-platelet therapy, however none has so far reached widespread application for this indication.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Calatzis, A., Klauss, V., Theisen, F., Schramm, W., Spannagl, M. (2008). Monitoring of Antiplatelet Therapy Using Whole Blood Aggregometry: Experiences and Approaches to Dose Adaptation. In: Scharrer, I., Schramm, W. (eds) 37th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73535-9_17
Download citation
DOI: https://doi.org/10.1007/978-3-540-73535-9_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-73534-2
Online ISBN: 978-3-540-73535-9
eBook Packages: MedicineMedicine (R0)